A company entrusted BlueReg to support them to prepare their first local market product launch in Europe, to allow the patient to obtain the medicine at the earliest point possible.
A European pharmaceutical company entrusted PharmaBlue (a BlueReg Company) as French «exploitant» with the responsibility of submitting, obtaining and implementing a French Early Access Program called “ATU” (Autorisation Temporaire d’Utilisation) for its orphan drug for patients in nominative and cohort…
A pharmaceutical company contacted BlueReg experts on promotional material for review of a non-promotional website and associated chatbot. The chatbot is an interactive tool with which the user can interact. Different information, in relation with the website on which the…
BlueReg made recommendations to a US based client on which Health Authorities in the European Union (EU) would be most relevant to consult throughout the development of their product. Following these recommendations, the client subsequently entrusted to BlueReg the authoring…